Nucresiran

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Transthyretin Amyloidosis With Cardiomyopathy

Drug Information

Target Indication

Transthyretin Amyloidosis With Cardiomyopathy

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ALNY

Alnylam Pharmaceuticals, Inc.

Related Pipeline

TTR-mediated Amyloidosis

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Hypertension

PH1

Acute Hepatic Porphyria